Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.
Mol Metab · 2022
Last updated 2026-05-28In mice and monkeys, brain cells that produce a chemical called cholecystokinin are needed for GLP-1 drugs like exendin-4 to reduce appetite and body weight. Blocking these cells stops the drugs from working, and activating a related pathway with GIP can lessen some of the drug’s unwanted effects, such as nausea.
AI summary of the abstract below.
| Journal | Mol Metab, 2022 |
|---|---|
| Citations | 62 |
| Relative citation ratio | 5.64 |
| NIH percentile | 94 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective medications to reduce appetite and body weight. These actions are centrally mediated; however, the neuronal substrates involved are poorly understood.
METHODS: We employed a combination of neuroanatomical, genetic, and behavioral approaches in the mouse to investigate the involvement of caudal brainstem cholecystokinin-expressing neurons in the effect of the GLP-1RA exendin-4. We further confirmed key neuroanatomical findings in the non-human primate brain.
RESULTS: We found that cholecystokinin-expressing neurons in the caudal brainstem are required for the anorectic and body weight-lowering effects of GLP-1RAs and for the induction of GLP-1RA-induced conditioned taste avoidance. We further show that, while cholecystokinin-expressing neurons are not a direct target for glucose-dependent insulinotropic peptide (GIP), GIP receptor activation results in a reduced recruitment of these GLP-1RA-responsive neurons and a selective reduction of conditioned taste avoidance.
CONCLUSIONS: In addition to disclosing a neuronal population required for the full appetite- and body weight-lowering effect of GLP-1RAs, our data also provide a novel framework for understanding and ameliorating GLP-1RA-induced nausea - a major factor for withdrawal from treatment.
Verbatim abstract via PubMed 34844019 ↗